Vontobel Holding Ltd. Sells 675 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Vontobel Holding Ltd. lessened its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 12.0% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 4,951 shares of the medical equipment provider’s stock after selling 675 shares during the quarter. Vontobel Holding Ltd.’s holdings in Lantheus were worth $543,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in LNTH. GAMMA Investing LLC raised its holdings in Lantheus by 184.1% in the 2nd quarter. GAMMA Investing LLC now owns 321 shares of the medical equipment provider’s stock worth $26,000 after purchasing an additional 208 shares in the last quarter. Fidelis Capital Partners LLC bought a new position in Lantheus in the first quarter worth about $34,000. FinTrust Capital Advisors LLC raised its stake in Lantheus by 53.6% in the first quarter. FinTrust Capital Advisors LLC now owns 665 shares of the medical equipment provider’s stock worth $41,000 after buying an additional 232 shares in the last quarter. Nkcfo LLC purchased a new stake in Lantheus in the second quarter worth about $47,000. Finally, UMB Bank n.a. boosted its position in Lantheus by 42.1% during the 3rd quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider’s stock valued at $47,000 after acquiring an additional 126 shares in the last quarter. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Analyst Ratings Changes

LNTH has been the subject of several research reports. Leerink Partners increased their target price on Lantheus from $106.00 to $127.00 and gave the stock an “outperform” rating in a research report on Thursday, July 11th. Redburn Atlantic assumed coverage on Lantheus in a research report on Tuesday, September 3rd. They set a “buy” rating and a $175.00 price objective for the company. JMP Securities dropped their target price on shares of Lantheus from $130.00 to $125.00 and set a “market outperform” rating on the stock in a report on Thursday, August 1st. B. Riley lifted their price target on shares of Lantheus from $105.00 to $146.00 and gave the company a “buy” rating in a research report on Thursday, July 25th. Finally, Truist Financial cut their price objective on shares of Lantheus from $141.00 to $135.00 and set a “buy” rating on the stock in a report on Thursday, August 1st. Two equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat.com, Lantheus has a consensus rating of “Moderate Buy” and a consensus price target of $126.00.

Lantheus Trading Down 4.0 %

Shares of NASDAQ:LNTH opened at $112.08 on Tuesday. The company has a debt-to-equity ratio of 0.55, a current ratio of 4.68 and a quick ratio of 4.41. Lantheus Holdings, Inc. has a 1 year low of $50.20 and a 1 year high of $126.89. The company has a market cap of $7.77 billion, a P/E ratio of 17.11 and a beta of 0.50. The stock’s fifty day moving average price is $106.11 and its 200-day moving average price is $91.74.

Lantheus (NASDAQ:LNTH) last posted its earnings results on Wednesday, July 31st. The medical equipment provider reported $1.61 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.68 by ($0.07). Lantheus had a net margin of 29.80% and a return on equity of 48.36%. The company had revenue of $394.10 million for the quarter, compared to the consensus estimate of $382.12 million. During the same quarter in the prior year, the company posted $1.40 EPS. Lantheus’s revenue was up 22.5% on a year-over-year basis. Sell-side analysts expect that Lantheus Holdings, Inc. will post 5.99 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Gerard Ber sold 15,500 shares of the stock in a transaction on Monday, August 12th. The stock was sold at an average price of $96.48, for a total transaction of $1,495,440.00. Following the transaction, the director now directly owns 21,221 shares of the company’s stock, valued at $2,047,402.08. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other Lantheus news, President Paul Blanchfield sold 2,000 shares of the company’s stock in a transaction that occurred on Thursday, August 8th. The shares were sold at an average price of $96.39, for a total transaction of $192,780.00. Following the completion of the sale, the president now directly owns 98,980 shares of the company’s stock, valued at approximately $9,540,682.20. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Gerard Ber sold 15,500 shares of Lantheus stock in a transaction on Monday, August 12th. The stock was sold at an average price of $96.48, for a total transaction of $1,495,440.00. Following the transaction, the director now owns 21,221 shares in the company, valued at $2,047,402.08. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 27,981 shares of company stock valued at $2,689,156. Company insiders own 1.50% of the company’s stock.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.